Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Slides:

Advertisements

Similar presentations

1 Copyright © 2010, Elsevier Inc. All rights Reserved Fig 4.1 Chapter 4.

Advertisements

ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre

Small-Cell Carcinoma in Association With a Mature Cystic Teratoma of the Ovary: A Case Report With Literature Review Karina E. Hew, Kimberley Studeman,

Volume 144, Issue 1, Pages (January 2017)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)

Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Eun-Jung Jung, George A. Calin Cancer Cell

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Volume 147, Issue 1, Pages 3-10 (October 2017)

Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

RNA sequencing (RNA-Seq) and its application in ovarian cancer

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 145, Issue 2, Pages (May 2017)

Volume 130, Issue 3, Pages (September 2013)

L.M. Bean, F.J. Sulzmaier, D.D. Schlaepfer

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

MicroRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer Riccardo Cazzoli, PhD, Fiamma Buttitta,

Volume 151, Issue 1, Pages (October 2018)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

MicroRNAs and Viral Infection

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 150, Issue 3, Pages (September 2018)

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Treatment of Colorectal Cancer

Volume 130, Issue 3, Pages (September 2013)

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 142, Issue 3, Pages (September 2016)

Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] Heini Lassus,

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 61, Issue 2, Pages (January 2016)

Volume 115, Issue 1, Pages (October 2009)

Presentation transcript:

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas D. Taylor, Cicek Gercel-Taylor Gynecologic Oncology Volume 116, Issue 1, (January 2010) DOI: 10.1016/j.ygyno.2009.10.045 Copyright © 2009 Elsevier Inc. Terms and Conditions

Fig. 2 Presence of small RNA associated with circulating EpCAM-positive exosomes from ovarian cancer patients. Panel A: representative analysis of the RNA isolated from tumor exosomes using Agilent 2100 Bioanalyzer. Panel B: agarose gel (1%) separation of total RNA from circulating exosomes and corresponding tumors. The low molecular weight RNA (LMW RNA) is indicated within the box. This total RNA was used as the starting material for microRNA profiling. Gynecologic Oncology 2010 116, DOI: (10.1016/j.ygyno.2009.10.045) Copyright © 2009 Elsevier Inc. Terms and Conditions